Special Issue

Vaccines and Vaccination: Historical Perspectives, Current Issues and Emerging/Evolving Themes

Message from the Guest Editors

In this Special Issue (SI) of *Vaccines*, we invite our academic and research colleagues to join us in submitting research papers and reviews on historical perspectives on human and animal infectious diseases and vaccine discovery and vaccination programs, the current issues facing vaccines for bacterial and viral diseases, vaccine discovery platforms and policy and regulatory frameworks in the field of vaccines and vaccination as a key public health initiative nationally and internationally, especially during large-scale pandemics such as the current COVID-19 pandemic and seasonal influenza outbreaks. The use of simulation and modelling strategies to track and predict the timecourse of infections and viral mutations during a pandemic will also be considered. Greater adoption of artificial intelligence (AI) to assist in rational design of future vaccines during pandemics will also be included in this SI. Finally, development of future efficacy and safety surveillance programs to provide real-time measurements of such signals in the face of exponential changes to the structure of the virus will also be the subject of this SI of Vaccines.

Guest Editors

Dr. Veysel Kayser

School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia

Prof. Dr. Igbal M. Ramzan

School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia

Deadline for manuscript submissions

closed (30 June 2024)



an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



mdpi.com/si/110226

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

